Corcept Therapeutics
Clinical trials sponsored by Corcept Therapeutics, explained in plain language.
-
New hope for cushing syndrome: Long-Term drug safety trial underway
Disease control OngoingThis study looks at the long-term safety of a drug called relacorilant for people with Cushing syndrome. It includes 125 adults who already completed a prior study and may benefit from continuing treatment. The main goal is to track any side effects over time.
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated May 17, 2026 04:37 UTC
-
New drug shows promise against fatty liver in Mid-Stage trial
Disease control OngoingThis study tests a new medicine called miricorilant in 175 adults with nonalcoholic steatohepatitis (NASH/MASH), a type of fatty liver disease that can lead to liver damage. Participants are randomly assigned to receive either the drug or a placebo, and neither they nor their doc…
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated May 17, 2026 04:33 UTC